tretinone
Tretinone, also known by its IUPAC name 4-oxo-4,5,6,7-tetradehydroretinoic acid, is a synthetic analogue of retinoic acid. It is structurally related to tretinoin (all‑trans retinoic acid) but contains a 4-oxo functional group that alters its binding affinity for retinoic acid receptors (RARs). The compound was first synthesized in the late 1970s during efforts to develop retinoid‐based therapeutics with improved potency and reduced cutaneous side effects.
Clinical research on tretinone has focused mainly on dermatological indications. In vitro studies demonstrate that it
The pharmacokinetic profile of tretinone indicates good skin penetration and a half‑life of approximately 24 hours within
Safety data suggest that tretinone is well tolerated in short‑term studies; common adverse reactions include transient